Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

T-cell lymphoma: the CAR-T revolution is coming

Natalie S. Grover, Anne W. Beaven

Blood (2024) 143 (13): 1201–1202.

https://doi.org/10.1182/blood.2023023443

Published: 2024

Journal Articles

Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma

Timothy J. Voorhees, Anne W. Beaven, Christopher Dittus, George E Hucks, J. Kaitlin Morrison, Catherine Joyce Arago Cheng, Tammy Cavallo, Steven I. Park, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo, Natalie S. Grover

Blood (2022) 140 (Supplement 1): 12723–12724.

https://doi.org/10.1182/blood-2022-156660

Published: 2022

Journal Articles

A Pilot Study Evaluating Acalabrutinib for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas

Christopher Dittus, Roy Ervin Strowd III, Kelly Hoye, Xianming Tan, Jordan Miller, Celeste Bello, Amir Khandani, Anne W. Beaven

Blood (2022) 140 (Supplement 1): 6616–6617.

https://doi.org/10.1182/blood-2022-165139

Published: 2022

Journal Articles

Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

Blood (2022) 140 (Supplement 1): 9431–9433.

https://doi.org/10.1182/blood-2022-170921

Published: 2022

Journal Articles

CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients

George E. Hucks, Jr., Barbara Savoldo, Gianpietro Dotti, Catherine Joyce Arago Cheng, Caroline Babinec, Kimberly A. Kasow, Michael Winstead, Arpita Patel, Cammie Presler, Natalie S Grover, J. Kaitlin Morrison, Anne W. Beaven, Marcie L. Riches, Thomas C. Shea, Jonathan S. Serody

Blood (2021) 138 (Supplement 1): 2829.

https://doi.org/10.1182/blood-2021-153968

Published: 2021

Journal Articles

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma

Natalie S Grover, Anastasia Ivanova, Dominic T. Moore, Catherine Joyce Arago Cheng, Caroline Babinec, John West, Tammy Cavallo, J. Kaitlin Morrison, Faith Brianne Buchanan, Edith Bowers, Christopher Dittus, Anne W. Beaven, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo

Blood (2021) 138 (Supplement 1): 742.

https://doi.org/10.1182/blood-2021-148102

Published: 2021

Journal Articles

S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements

Elizabeth A Brem, Hongli Li, Anne W. Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh, Rebecca L. Olin, Norah Lynn Henry, Hildy Dilon, Richard F. Little, Cara Laubach, Michael L. Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 3565.

https://doi.org/10.1182/blood-2021-148193

Published: 2021

Journal Articles

A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus

Christopher Dittus, Natalie S Grover, Tarsheen Sethi, Jonathon B. Cohen, Alfredo Voloschin, Janhvi Rabadey, Xianming Tan, Anne W. Beaven, Steven I. Park

Blood (2021) 138 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2021-145133

Published: 2021

Journal Articles

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-138542

Published: 2020

Journal Articles

Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-137620

Published: 2020

Journal Articles

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival

Cristiana A Costa, DO, Bassem I Zaki, MD, Stephanie P Yen, MD, Eric S Winer, MD, Helen Ryan, MD, Darcie Findley, Sara R Metzler, RN, Lynn Shaw, RN, Annie Tsui, RN, Todd A MacKenzie, PhD, Anne W Beaven, MD, Frederick Lansigan, MD

Blood (2016) 128 (22): 1793.

https://doi.org/10.1182/blood.V128.22.1793.1793

Published: 2016

Journal Articles

Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Zanetta S. Lamar, MD, Scott Isom, MS, Rakhee Vaidya, MD, Anne W Beaven, MD, Zachariah A. McIver, DO

Blood (2016) 128 (22): 4163.

https://doi.org/10.1182/blood.V128.22.4163.4163

Published: 2016

Journal Articles

Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies

Carla Casulo, MD, Jia Ruan, MD PhD, Nam H. Dang, MD PhD, Lia Gore, MD, Catherine Diefenbach, MD, Anne W Beaven, MD, Januario E. Castro, MD, Pierluigi Porcu, MD, Leonardo Faoro, MD, Jakob Dupont, MD, Ann Kapoun, PhD, Min Wang, PhD, Kristin McGuire, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 5108.

https://doi.org/10.1182/blood.V128.22.5108.5108

Published: 2016

Journal Articles

Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial

Patrick B. Johnston, MD PhD, Amanda F. Cashen, MD, Petros G. Nikolinakos, MD, Anne W Beaven, MD, Stefan Klaus Barta, MDMRCP,MS, Gajanan Bhat, PhD, Tao Song, Mi Rim Choi, MD, Lee F. Allen, MD PhD, Sven de Vos, MD PhD, Yasuhiro Oki, MD, Changchun Deng, MDPhD, Francine M Foss, MD

Blood (2015) 126 (23): 253.

https://doi.org/10.1182/blood.V126.23.253.253

Published: 2015

Journal Articles

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Results of Fol-Brite

Frederick Lansigan, MD, Bassem I Zaki, MD, Stephanie P Yen, MD, Eric S Winer, MD, Helen Ryan, MD, Darcie L Findley, Sara R Metzler, RN, Lynn Shaw, RN, Annie Tsui, RN, Todd MacKenzie, PhD, Anne W Beaven, MD

Blood (2014) 124 (21): 1733.

https://doi.org/10.1182/blood.V124.21.1733.1733

Published: 2014

Journal Articles

Chemical Genomics Reveals JAK STAT Activation As a Mechanism of Resistance to HDAC Inhibitors in B Cell Lymphomas

Matthew S. McKinney, MD, Anne W Beaven, MD, Andrea Moffitt, Jason Landon Smith, MD, Eric Lock, PhD, Dereje Jima, Jane Healy, MD PhD, Guojie Li, Adrienne Greenough, PhD, Cassandra L Love, MS, Xiao Yi Yang, MD, David Dunson, PhD, Herbert Kim Lyerly, MD, Leon Bernal-Mizrachi, MD, Randy D. Gascoyne, MD, Sandeep S. Dave, MD

Blood (2014) 124 (21): 271.

https://doi.org/10.1182/blood.V124.21.271.271

Published: 2014

Journal Articles

A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial

Ranjana H. Advani, MD, Stephen M. Ansell, M.D., Ph.D., Mary J Lechowicz, MD, Anne W Beaven, MD, Fausto R. Loberiza, Jr., MD, MS, Kenneth R Carson, MD, Andrew M Evens, DO, MSc, Francine M. Foss, MD, Steven M. Horwitz, MD, Barbara Pro, MD, Lauren Pinter-Brown, MD, Sonali M. Smith, MD, Andrei R. Shustov, MD, Kerry J. Savage, MD, MSc, Julie M Vose, MD, MBA

Blood (2013) 122 (21): 3044.

https://doi.org/10.1182/blood.V122.21.3044.3044

Published: 2013

Journal Articles

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium

Andrei R. Shustov, MD, Wyndham H Wilson, MD, PhD, Anne W Beaven, MD, Kerry J. Savage, MD, MSc, Kenneth R. Carson, MD, Francisco J. Hernandez-Ilizaliturri, MD, Sindhu Cherian, MD, Ted A. Gooley, PhD, Julie M Vose, MD, MBA

Blood (2013) 122 (21): 3032.

https://doi.org/10.1182/blood.V122.21.3032.3032

Published: 2013

Journal Articles

Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma

Blood (2013) 122 (21): 842.

https://doi.org/10.1182/blood.V122.21.842.842

Published: 2013

Journal Articles

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Danielle M. Brander, MD, Anne W Beaven, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Cristina Gasparetto, MD, Thomas C. Shea, MD, Carlos deCastro, Joseph O. Moore, MD, David A. Rizzieri, MD

Blood (2012) 120 (21): 1626.

https://doi.org/10.1182/blood.V120.21.1626.1626

Published: 2012

NARROW

T-cell lymphoma: the CAR-T revolution is coming

Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma

A Pilot Study Evaluating Acalabrutinib for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas

Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients

CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma

A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival

Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies

Safe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 Trial

Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Results of Fol-Brite

Chemical Genomics Reveals JAK STAT Activation As a Mechanism of Resistance to HDAC Inhibitors in B Cell Lymphomas

A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium

Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only